Chaussade S - Search Results

1

Oral therapies in digestive oncology (Review).

Prieux-Klotz C, Dermine S, Palmieri LJ, Lavole J, Chaussade S, Brezault C, Coriat R. Prieux-Klotz C, et al. Among authors: chaussade s. Oncol Rep. 2020 Jun;43(6):1719-1728. doi: 10.3892/or.2020.7555. Epub 2020 Mar 20. Oncol Rep. 2020. PMID: 32236638 Review.

2

Local Therapy in Advanced Cholangiocarcinoma: A Review of Current Endoscopic, Medical, and Oncologic Treatment Options.

Jung CFM, Lavole J, Barret M, Abou Ali E, Palmieri LJ, Dermine S, Barré A, Chaussade S, Coriat R. Jung CFM, et al. Among authors: chaussade s. Oncology. 2019;97(4):191-201. doi: 10.1159/000500832. Epub 2019 Jul 2. Oncology. 2019. PMID: 31266042 Review.

3

The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.

Palmieri LJ, Lavolé J, Dermine S, Brezault C, Dhooge M, Barré A, Chaussade S, Coriat R. Palmieri LJ, et al. Among authors: chaussade s. Pharmacol Ther. 2020 Jun;210:107517. doi: 10.1016/j.pharmthera.2020.107517. Epub 2020 Feb 25. Pharmacol Ther. 2020. PMID: 32109491 Review.

4

[Neuroendocrine pancreatic tumors and helpfulness of targeted therapies].

Vaysse T, Coriat R, Perkins G, Dhooge M, Brezault C, Chaussade S. Vaysse T, et al. Among authors: chaussade s. Presse Med. 2013 Jun;42(6 Pt 1):961-7. doi: 10.1016/j.lpm.2012.06.017. Epub 2012 Sep 23. Presse Med. 2013. PMID: 23009947 Review. French.

5

Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.

Dhooge M, Coriat R, Mir O, Perkins G, Brezault C, Boudou-Rouquette P, Goldwasser F, Chaussade S. Dhooge M, et al. Among authors: chaussade s. Oncology. 2013;84(1):32-8. doi: 10.1159/000342763. Epub 2012 Oct 16. Oncology. 2013. PMID: 23076239

6

Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.

Dréanic J, Maillet M, Dhooge M, Mir O, Brezault C, Goldwasser F, Chaussade S, Coriat R. Dréanic J, et al. Among authors: chaussade s. Med Oncol. 2013;30(3):656. doi: 10.1007/s12032-013-0656-y. Epub 2013 Jul 10. Med Oncol. 2013. PMID: 23839775

7

A prognostic indicator of survival in metastatic colorectal cancer patients in the era of molecular-targeted agents: the modified Glasgow Prognostic Score.

Dreanic J, Dhooge M, Brezault C, Mir O, Chaussade S, Coriat R. Dreanic J, et al. Among authors: chaussade s. Oncology. 2014;86(1):44-5. doi: 10.1159/000356879. Epub 2013 Dec 20. Oncology. 2014. PMID: 24356426 No abstract available.

8

The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.

Maillet M, Dréanic J, Dhooge M, Mir O, Brezault C, Goldwasser F, Chaussade S, Coriat R. Maillet M, et al. Among authors: chaussade s. Anticancer Drugs. 2014 Nov;25(10):1215-9. doi: 10.1097/CAD.0000000000000129. Anticancer Drugs. 2014. PMID: 24858536

9

Gastric Carcinoma at the Era of Targeted Therapies.

Dreanic J, Dhooge M, Sion E, Brezault C, Chaussade S, Coriat R. Dreanic J, et al. Among authors: chaussade s. Curr Drug Targets. 2016;17(15):1818-1826. doi: 10.2174/1389450116666150506111327. Curr Drug Targets. 2016. PMID: 25944013 Review.

10

Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.

Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, Abitbol V, Chaussade S, Coriat R. Prieux-Klotz C, et al. Among authors: chaussade s. Target Oncol. 2017 Jun;12(3):301-308. doi: 10.1007/s11523-017-0495-4. Target Oncol. 2017. PMID: 28540478

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

454 results

Search Page